A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responses

IntroductionMetastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV) represent a novel approach to immunotherapy for patients with MUM.MethodsWe...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Katherine E. R. Smith, Kah-Whye Peng, Jose S. Pulido, Adam J. Weisbrod, Carrie A. Strand, Jacob B. Allred, Alysha N. Newsom, Lianwen Zhang, Nandakumar Packiriswamy, Timothy Kottke, Jason M. Tonne, Madelyn Moore, Heather N. Montane, Lisa A. Kottschade, Robert R. McWilliams, Arkadiusz Z. Dudek, Yiyi Yan, Anastasios Dimou, Svetomir N. Markovic, Mark J. Federspiel, Richard G. Vile, Roxana S. Dronca, Matthew S. Block
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Subjects:	oncolytic virus uveal melanoma phase 1 immunotherapy epitope spreading
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1279387/full